TY - JOUR
T1 - Ten-year survival and risk of relapse for testicular cancer
T2 - A EUROCARE high resolution study
AU - Sant, Milena
AU - Aareleid, Tiiu
AU - Artioli, Maria Elisa
AU - Berrino, Franco
AU - Coebergh, Jan Willem
AU - Colonna, Marc
AU - Forman, David
AU - Hedèlin, Guy
AU - Rachtan, Jadwiga
AU - Lutz, Jean Michel
AU - Otter, Renée
AU - Raverdy, Nicole
AU - Plesko I, Ivan
AU - Primic, Maja Žakelj
AU - Tagliabue, Giovanna
PY - 2007/2
Y1 - 2007/2
N2 - Effective treatments for testicular cancer have been available since the 1970s, yet EUROCARE uncovered marked inter-country survival differences for this disease. To investigate these differences, we reviewed clinical records of 1350 testicular cancer cases diagnosed during 1987-1992 from 13 population-based cancer registries in nine European countries. Patients were followed up for life status and relapse. Ten-year observed survival was estimated by the Kaplan-Meier method. Cox multivariable analyses were performed separately for seminomas and non-seminomas. Overall, 66% of seminomas and 36% of non-seminomas were limited to the testis. Ten-year survival was 63% (Estonia) to 94% (Switzerland, Slovenia) for seminoma; 47% (Estonia) to 90% (Yorkshire, UK, The Netherlands) for non-seminoma. Multivariable analysis adjusted for country, age and stage showed that hazard ratios (HRs) of death differed little between western European registries, and were mainly attributable to differing stage at diagnosis. Significantly higher than reference HRs in Estonia and Poland suggest inadequacy or unavailability of treatments.
AB - Effective treatments for testicular cancer have been available since the 1970s, yet EUROCARE uncovered marked inter-country survival differences for this disease. To investigate these differences, we reviewed clinical records of 1350 testicular cancer cases diagnosed during 1987-1992 from 13 population-based cancer registries in nine European countries. Patients were followed up for life status and relapse. Ten-year observed survival was estimated by the Kaplan-Meier method. Cox multivariable analyses were performed separately for seminomas and non-seminomas. Overall, 66% of seminomas and 36% of non-seminomas were limited to the testis. Ten-year survival was 63% (Estonia) to 94% (Switzerland, Slovenia) for seminoma; 47% (Estonia) to 90% (Yorkshire, UK, The Netherlands) for non-seminoma. Multivariable analysis adjusted for country, age and stage showed that hazard ratios (HRs) of death differed little between western European registries, and were mainly attributable to differing stage at diagnosis. Significantly higher than reference HRs in Estonia and Poland suggest inadequacy or unavailability of treatments.
KW - Population cancer registries
KW - Stage
KW - Survival
KW - Testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=33846570845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846570845&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.11.006
DO - 10.1016/j.ejca.2006.11.006
M3 - Article
C2 - 17222545
AN - SCOPUS:33846570845
VL - 43
SP - 585
EP - 592
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 3
ER -